The board of directors of Amgen (NASDAQ:AMGN) declared on Wednesday its dividend of USD1.76 per share for the Q2 2021.

This dividend is due on 8 June 2021 to all stockholders of record as of the close of business as of 17 May 2021.

According to the company, it is engaged in discovering, developing, manufacturing and delivering innovative human therapeutics via advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

A biotechnology pioneer, the company has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.